New at ESMO 2017, adjuvant dabrafenib/trametinib in stage III melanoma shows 'impressive' results in relapse-free survival.

Clinical trial data from ESMO 2017 have immediate clinical implications for the treatment of locally advanced lung cancers, according to Dr Mark Kris.

Traditional Chinese medicine and other alternative therapies have a lot to offer patients with cancer, says Dr Kerr. Just follow three simple 'rules' when choosing.

Simplifying clinical research is possible and desirable, says Dr John Marshall.

A recent study relates future risk to current risk for advanced colorectal cancer. Dr Kerr suggests adding genetic testing to further improve diagnosis.

Although not a year for big advances in colorectal cancer, exciting research with current standards was presented at ESMO 2017.

The benefit of prescribing exercise for cancer-related fatigue is making more sense.

Dr Gerald Chodak provides his perspective on updated data from a large trial of surveillance versus definitive treatment for prostate cancer, including strengths and weaknesses of the study.

An epidemic of greed is sweeping through the field of oncology. We need to fix it NOW, says Dr Lundberg.

With the examples of pembrolizumab and larotrectinib, Dr Markman discusses how precision cancer medicine will likely change the landscape of cancer therapy.